Cowen And Company, LLC Adverum Biotechnologies, Inc. Transaction History

Cowen And Company, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $1.2 Million - $1.9 Million	-972,176 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $1.69 Million - $2.33 Million	972,176 New	972,176 $1.71 Million
Q4 2020 Feb 08, 2021	SELL	$9.84 - $14.26 $1.38 Million - $1.99 Million	-139,781 Closed	0 $0
Q3 2020 Nov 03, 2020	SELL	$10.3 - $21.64 $210,480 - $442,213	-20,435 Reduced 12.75%	139,781 $1.44 Million
Q2 2020 Aug 13, 2020	SELL	$8.53 - $25.64 $498,220 - $1.5 Million	-58,408 Reduced 26.72%	160,216 $3.35 Million
Q1 2020 May 11, 2020	SELL	$7.98 - $16.32 $143,312 - $293,090	-17,959 Reduced 7.59%	218,624 $2.14 Million
Q4 2019 Feb 11, 2020	BUY	$5.12 - $12.22 $1.21 Million - $2.89 Million	236,583 New	236,583 $2.73 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.